Shares of biotech company Oncothyreon (NASDAQ: ONTY) fell more than 50% yesterday. The company released Phase 3 data for its drug Stimuvax, an experimental vaccine that treats non-small cell lung cancer, which showed that the drug failed to improve overall survival for patients in the clinical trial. In this video, Motley Fool health-care analysts Max Macaluso and Brenton Flynn take us through the details.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Oncothyreon was down big yesterday - what happened?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso, Ph.D. has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Geron
GERN
$1.26
(-1.56%)
$0.02
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Could GLP-1 Drugs Potentially Help Treat Cancer? 1 Promising Study Suggests They Might
3 Things You Need to Know if You Buy Walgreens Stock Today
Where Will Intuitive Surgical Be in 5 Years?
The Smartest Dividend Stocks to Buy With $350 Right Now
Down 74% Over the Past Year, Is Moderna Stock a Buy?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.